Drugs / GSK2816126
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02082977 | Apr 2014 → Jun 2017 | cancer | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2816126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02082977 ↗ |
| Action | Inhibit | “Histone-lysine N-methyltransferase EZH2 inhibitor” CHEMBL3287735 ↗ |
| Modality | Small molecule | — CHEMBL3287735 ↗ |
| Route | Intravenous | “given twice weekly by intravenous (IV) infusion.” NCT02082977 ↗ |
| Target | EZH2 | “Histone-lysine N-methyltransferase EZH2 inhibitor” CHEMBL3287735 ↗ |